Patients with critical limb ischemia might be better off if they opt for endovascular-first treatment over an open surgical bypass, a Circulation: Cardiovascular Quality and Outcomes study suggests.

The FDA issued an advisory August 7 updating healthcare providers and the public on its stance regarding the long-term safety of paclitaxel-coated and -eluting devices, sharing that its expert panel had indeed identified a late mortality signal associated with the devices.

TARA Biosystems’ “heart-on-a-chip” system successfully replicates human drug responses to CV medications without having to risk cardiotoxicity in human testing, researchers from TARA and GlaxoSmithKline announced August 6.

People with osteoarthritis are 23% more likely to develop CVD than their non-arthritic counterparts if they regularly use NSAIDs, according to research published in Arthritis & Rheumatology August 6.

An editorial published in The Lancet August 2 scrutinized JUUL Labs’ participation in and sponsorship of e-cigarette research in the U.S., finding the vaping giant fell short in seven of eight categories designed to test ethical integrity.

Individuals infected with hepatitis C are at a significantly increased risk of developing heart disease, according to a Lancet analysis that also found hep C-linked CVD is responsible for 1.5 million disability-adjusted life-years (DALYs) annually.

An antioxidant compound found in soybeans might protect the heart from cannabis-related CV damage, according to work presented at the American Heart Association’s Basic Cardiovascular Sciences 2019 Scientific Sessions.

Researchers at the University of Michigan have developed technology that flags stroke victims at the greatest risk for atrial fibrillation after an event, trumping standard methods of risk stratification to achieve greater accuracy.